- Home
- APM vs CLRB Comparison
APM vs CLRB Comparison
Compare APM & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APM | CLRB |
|---|---|---|
| Founded | 2010 | 2002 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.8M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | APM | CLRB |
|---|---|---|
| Price | $1.08 | $3.14 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 49.4K | ★ 69.1K |
| Earning Date | 12-18-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.69 | $2.45 |
| 52 Week High | $4.47 | $20.60 |
Technical Indicators
Market Signals| Indicator | APM | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 47.76 |
| Support Level | $1.02 | $3.15 |
| Resistance Level | $1.08 | $3.72 |
| Average True Range (ATR) | 0.08 | 0.28 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 19.51 | 49.67 |
Price Performance
Historical ComparisonAbout APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.